Carlos Roca

Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Annachiara Gandini, Manuela Bartolini, Daniele Tedesco et al. · Journal of Medicinal Chemistry · 2018 · 103 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery

Ignacio Ponzoni, Víctor Sebastián-Pérez, Carlos Requeña et al. · Scientific Reports · 2017 · 77 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer’s Disease

Ignacio Ponzoni, Víctor Sebastián-Pérez, María Jimena Martínez et al. · Scientific Reports · 2019 · 75 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

AI in drug development: a multidisciplinary perspective

Víctor Gallego, Roi Naveiro, Carlos Roca et al. · Molecular Diversity · 2021 · 70 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +6

Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

Daniel I. Pérez, Carlos Roca, Cara Anderson et al. · Journal of Medicinal Chemistry · 2017 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17